The HealthAlpha Podcast

What happens when a doctor sees a healthcare problem so big she can't ignore it? In this episode, I sit down with Dr. Sue-Ann Toh, endocrinologist, researcher, and co-founder of Novi Health, who left the traditional path of medicine to tackle Asia's growing diabetes and metabolic health crisis head-on. From leading one of Singapore's largest Type 2 diabetes studies to building a preven...

What if the biggest opportunities in pharma aren't new drugs at all? In this episode, I sit down with Sreevatsa Natarajan, CEO of Revio Therapeutics, who has spent 25+ years developing medicines across companies like Vertex, Dr. Reddy’s, Glenmark, and more. We explore why many approved drugs are still "unfinished," how drug repurposing and drug reformulation can unlock massive value,...

90% of serotonin is produced in the gut… and your microbiome could influence everything from immunity to Parkinson’s and even cancer risk. In this episode, Dr. Jeremy Lim, the co-founder of Amili, breaks down how the gut microbiome really works, why ultra-processed foods and antibiotics may be quietly damaging us, and how microbiome transplants are already changing lives. We also get into the scie...

I didn’t expect a conversation about CDMOs to sound this much like high-stakes strategy, global politics, and biotech survival. In this episode, I sit down with Nick Wigdahl, former Roche leader and now founder of Pharmagro, to unpack how pharmaceutical manufacturing actually works behind the scenes, why companies like Samsung Biologics and WuXi became global giants, and how India, China, and Kore...

I thought biotech was about breakthroughs—until I realised it’s really about surviving the funding game. In this episode, I sit down with Kiran Asarpota, a biotech operator who’s lived the full cycle—from raising $300M and taking a company public on Nasdaq to navigating the brutal reality of shutdowns. We get into what biotech startups don’t tell you—why early-stage funding is drying up, what “de-...

I thought healthcare investing was about money — turns out it’s about fixing a system that’s already cracking. In this episode, I sit down with Seemant Jauhari — from corporate beginnings to building his own healthcare fund and now Partner at Jungle Ventures — to unpack what’s really happening inside healthcare startups and venture capital in Asia. We get into why healthcare is one of the most res...

In this episode of HealthAlpha , host Sushaant sits down with Shi-Ying Lau, Managing Partner at Adaptive Capital, to unpack how healthcare investors really think and what founders need to know to raise smarter capital in 2026 and beyond. We go deep into AI-powered diagnostics, early cancer detection, the bias in women’s health investment, and wearable health tech , and explore how Asia-based start...

Most cancer deaths are caused by metastasis , not the primary tumor.  In this episode, Sushaant speaks with Arnab Roy Chowdhury about how his team at Metastop is tackling metastasis as a separate disease , using patient data, lab models, and machine learning to understand why cancer spreads and how to stop it. Their research points to cancer cell adaptation as the key bottleneck in metastasis. The...

In this episode of HealthAlpha , Sushaant interviews Dr. Ramesh Rajentheran to discuss the factors driving rising medical costs in Southeast Asia, challenges within health insurance companies, and ongoing difficulties patients face with claims and reimbursements. The discussion also addresses the role of regulation and brokers, the potential for AI to streamline administrative tasks, and the feasi...

In the debut episode of Health Alpha, host Sushaant sits down with Jyothish , the founder of LivEzee , to discuss one of the most pressing demographic shifts of our time: the "super-aging" of Asia. While the world focuses on youth, a silent revolution is happening in countries like India, where the elderly population is expected to grow by 134% over the next three decades. Nowhere is thi...